Jock-alchy is a term used to describe a disease that affects cats, dogs and other animals.
The condition is caused by an immune system that produces a protein called CD19 that is responsible for the allergic reactions that can cause severe itching.
It is believed that the immune system is responsible in some cases for the itching, but there is no evidence to support this.
In addition, there are no drugs or treatments available to treat Jock’s itch.
Now, a team of scientists has developed a treatment for Jock that can stop the symptoms and also prevent cats from developing this disease.
Dr. Joseph F. Kuehner, a professor of medicine at the Johns Hopkins University School of Medicine, is the lead author of the study, published online this week in the journal Science Translational Medicine.
“We were able to create a protein that can kill CD19 and prevent Jock itching in cats,” said Dr. Kueshner.
“That makes the treatment more likely to be used in cats.”
In addition to being a new way to treat the itch, this treatment also offers benefits for people with allergies, which include asthma and allergies to peanuts and dairy products.
Kuerhner and Kuehler have been studying this new therapy for a number of years.
In 2014, they reported on a study published in the Proceedings of the National Academy of Sciences that found that a single dose of the Jock medicine had no negative side effects on a group of 10 people who were allergic to peanut and other dairy products, or to peanuts or dairy products with a history of allergic reactions.
“It is a novel molecule, so we knew we were going to need to look for additional mechanisms to be able to see if it could be effective,” said Kuehners co-investigator, Dr. Matthew Hoch, who studies allergic diseases at the University of Chicago.
The team studied the protein’s activity in mouse blood cells, in order to see whether it could interact with a number in the immune systems of mice.
They found that the Jocks proteins did not interfere with the cells’ ability to produce the antibodies that protect the cells from the infection.
Instead, they inhibited the production of the anti-CD19 antibodies, preventing the cells and the mice from developing the allergy.
“We think that the mice were protecting themselves,” said Hoch.
The new treatment has not been tested in humans yet, but the team is continuing to test it on mice.
The next step in their research is to determine if it works in humans, and if it does, the treatment will be used to treat allergies to other allergens.